QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable GrowthBusiness Wire • 01/12/26
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 MillionBusiness Wire • 12/18/25
Qiagen (QGEN) Up 6.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/25
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/02/25
Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion TranscriptSeeking Alpha • 11/21/25
Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/19/25
CellBxHealth rises on Qiagen tie-up to push Parsortix into more drug-development projectsProactive Investors • 11/18/25
CellBxHealth strikes co-marketing deal with Qiagen to widen use of Parsortix cancer platformProactive Investors • 11/18/25
Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference TranscriptSeeking Alpha • 11/17/25
Qiagen (QGEN) International Revenue in Focus: Trends and ExpectationsZacks Investment Research • 11/17/25
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025Business Wire • 11/10/25
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share RepurchaseBusiness Wire • 11/04/25
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutionsBusiness Wire • 11/04/25
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample ProcessingBusiness Wire • 10/28/25